The phase III monarchE trial reported that the addition of 2 years of abemaciclib to adjuvant ET improved invasive disease free (IDFS) survival in high-risk early-stage ER+/HER2-breast cancer (O'Shaughnessy et al., 2021). The gene discussed is ESR1; the disease is breast cancer.